MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergics"

  • 2019 International Congress

    The Dutch Parkinson and Microbiome Study (DUPARM): Gut Microbiome Composition of Treatment-Naïve De Novo Parkinson’s Disease Patients

    J. Boertien, S. Vander Zee, T. van Laar (Groningen, Netherlands)

    Objective: To establish the gut microbiome composition of de novo Parkinson’s disease (PD) patients with no history of dopaminergic medication use. Background: PD is often…
  • 2019 International Congress

    Differential temporal processing across Lewy body disorders and relation to cognitive fluctuations

    E. Matar, J. Phillips, K. Ehgoetz Martens, G. Halliday, S. Lewis (Sydney, Australia)

    Objective: To characterize differences in interval timing between patients with Parkinson’s disease and Dementia with Lewy bodies (DLB) and evaluate their relationship to cognitive fluctuations…
  • 2019 International Congress

    Anxiety and dopaminergic stimulation in patients with Parkinson´s disease.

    A. Camacho Nieto, AR. Franco Salinas, L. Ruiz-Escribano Menchen, MJ. Gallardo Alcañiz, JP. Cabello Rosa, J. Vaamonde Gamo (Ciudad Real, Spain)

    Objective: To report two patients with Parkinson disease and describe the response of this non motor symptom to dopaminergic therapy. Background: Anxiety is frequent comorbidity…
  • 2018 International Congress

    Patient Perceptions of Dopaminergic Therapy Withdrawal in Parkinson’s disease

    N. Kukreti, P. Trujillo-Diaz, N. Van Wouwe, D. Claassen (Nashville, TN, USA)

    Objective: To survey Parkinson’s disease (PD) patients regarding their willingness and experience in withdrawal of their dopaminergic medications. Background: Parkinson’s disease patients are asked to…
  • 2018 International Congress

    Vowel characteristics associated with Parkinson’s disease in Cantonese

    N. Leung, E. Tong, M. Ng (Pokfulam, Hong Kong)

    Objective: Dopaminergic treatment has been reported to help motor problem associated with Parkinson's disease (PD), but not speech motor. The current study examined vowel articulation…
  • 2018 International Congress

    Effect of Urinary Dysfunction on Fatigue Syndrome in Parkinson’s disease

    V. Datieva, O. Levin (Moscow, Russian Federation)

    Objective: to investigate the relationship between urinary dysfunction and fatigue syndrome in Parkinson`s disease Background: Fatigue syndrome (FS) is an overwhelming sense of tiredness, lack…
  • 2018 International Congress

    Dopaminergics are alternative for the treatment of Bell`s paralysis in acute period

    A. Azimov, R. Sadykov, G. Rakhimbaeva, F. Azimov (Tashkent, Uzbekistan)

    Objective: To study the possibility of using dopaminergic medicines for the treatment of Bell`s paralysis in acute period. Background: In previous reports we conjectured that…
  • 2018 International Congress

    Could the rate of dopaminergic medications reduction affect outcome after STN-DBS?

    S. Alusi (Liverpool, United Kingdom)

    Objective: A retrospective analysis of the rate of dopaminergic drugs reduction following subthalamic nucleus Deep Brain Stimulation (STN-DBS) in a group of Parkinson’s disease patients…
  • 2017 International Congress

    Maximising decrease in Dopaminergic drugs and increase in ON time following Bilateral STN DBS using constant current for Advanced Parkinsons Disease

    S. SANYAL (CALCUTTA (KOLKATA), India)

    Objective: To evaluate the decrease in Dopaminergic drug dosage and increase in ON time following Bilateral STN DBS using constant current for Advanced PD Background:…
  • 2017 International Congress

    Spinal cord stimulation reduces freezing of gait and improves gait in advanced Parkinson’s disease

    O. Samotus, N. Kumar, S. Memar, M. Jog (London, ON, Canada)

    Objective: The primary objective was to investigate the therapeutic effect of spinal cord stimulation (SCS) on gait dysfunction including freezing of gait (FOG) in advanced…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley